Last reviewed · How we verify
Deferiprone, dose level 1
Deferiprone, dose level 1 is a Small molecule drug developed by Consorzio per Valutazioni Biologiche e Farmacologiche. It is currently in Phase 2 development. Also known as: DFP.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Deferiprone, dose level 1 |
|---|---|
| Also known as | DFP |
| Sponsor | Consorzio per Valutazioni Biologiche e Farmacologiche |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia (PHASE2)
- Vitamin E Supplementation for Children With Transfusion Dependent Beta Thalassemia on Different Iron Chelation Regimen (NA)
- Study of Parkinson's Early Stage With Deferiprone (PHASE2)
- The Effectiveness of the Letrozole-induced Endometrial Preparation Protocol in Frozen-thawed Embryo Transfer (FET) (NA)
- Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet (PHASE2)
- Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias (PHASE4)
- Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN) (PHASE3)
- Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Deferiprone, dose level 1 CI brief — competitive landscape report
- Deferiprone, dose level 1 updates RSS · CI watch RSS
- Consorzio per Valutazioni Biologiche e Farmacologiche portfolio CI
Frequently asked questions about Deferiprone, dose level 1
What is Deferiprone, dose level 1?
Who makes Deferiprone, dose level 1?
Is Deferiprone, dose level 1 also known as anything else?
What development phase is Deferiprone, dose level 1 in?
Related
- Manufacturer: Consorzio per Valutazioni Biologiche e Farmacologiche — full pipeline
- Also known as: DFP
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing